News

Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency.  

  • The Fertility Partnership acquires VivaNeo to create Northern Europe’s leading Fertility Group

    The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.

    Read the whole news at Cision
  • Impilo acquires The Fertility Partnership, a leading European IVF platform

    Impilo has today signed an agreement to acquire a majority holding in The Fertility Partnership (“TFP”), one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with activities in the UK and Poland. The group comprises 8 IVF clinics in the UK, which in turn are supported by a network of 27 satellites, thus enabling local patient care; 2 IVF clinics in Poland, the leading independent provider of ultrasound services through a network of 88 ultrasound across the UK; and a nascent hormone treatment business.

    Read the whole news at Cision
  • Impilo increases its ownership in Humana and becomes the largest shareholder

    Impilo increases its shareholding in Swedish care company Humana AB (publ) (”Humana”), through the acquisition of approximately 6 percent of the shares outstanding from Argan Capital. Through this investment, Impilo becomes the largest shareholder in Humana with a total shareholding of 18.5 percent of the shares outstanding.

    Read the whole news at Cision
  • Impilo becomes second largest shareholder in Humana

    STOCKHOLM, January 14 2019 – Today, Impilo announces that it has entered into an agreement to acquire the equivalent of 12.5 percent of the shares in Swedish care company Humana AB (publ) (”Humana”) from Humana’s largest shareholder, Argan Capital. Through this investment, Impilo becomes the second largest shareholder in Humana and intends to contribute actively in the continued development of the company. Humana was founded in 2001 and is a leading provider of care services in the Nordic region, currently with c. 15,000 employees and a turnover of SEK 6.6bn. The company serves about 8,000 clients in Sweden, Norway, Finland and Denmark.

    Read the whole news at Cision
  • Immedica acquires the rights for Ravicti® and Ammonaps® outside North America and Japan

    Today, through its entity Medical Need Europe AB, Immedica has acquired rights for the products Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD), in all territories outside North America and Japan from Horizon Pharma plc (NASDAQ: HZNP) (Horizon). The deal encompasses all IP and commercial and distribution rights for the two products in the territories. Horizon will retain rights for the products in North America and Japan. More information is available at www.immedica.com or www.medicalneed.com

    Read the whole news at Cision
  • Impilo launches Immedica – a platform for pan-European niche specialty pharma launch, commercialization and distribution services

    Impilo has launched Immedica Pharma – a pan-European specialty pharma commercialization and distribution platform. Immedica’s plan is to quickly establish a fast-growing EUR 100m+ leading pan-European niche specialty pharma portfolio composed of partner products as well as proprietary products rights – and spanning from pre-approval stage through peak sales. This will be achieved through world-class launch, commercialization, and distribution capabilities lead by a management team with a very strong and established track record within niche specialty pharma.

    Read the whole news at Cision
  • Impilo invests in Swedish HIV diagnostics company Cavidi

    Impilo has invested in a 29% stake in Cavidi AB, an Uppsala-based diagnostics company focused on HIV Viral Load monitoring. Cavidi has developed a new fully automated viral load diagnostic platform. This platform, Ziva™, aims to meet the need for cost-effective monitoring in high-disease burden countries.

    Read the whole news at Cision
  • Impilo adds senior resources

    Impilo, the Nordic investment company focusing on healthcare and health-related investments has recruited two new team members. Impilo now has eight investment professionals and three industrial partners with complementary backgrounds.

    Read the whole news at Cision
  • Impilo acquires Ferrosan Medical Devices, a global leading manufacturer of hemostats

    Impilo has acquired 37 percent of the shares in Ferrosan Medical Devices (FeMD) that develops and produces hemostatic products used to stop bleeding during surgery, as well as miniature electrical engineering used in equipment for regional anesthesia and minimal invasive surgery.

    Read the whole news at Cision
  • Healthcare focused investment company Impilo established

    The investment company Impilo has now been established. The Sweden-based company will focus on the pharmaceutical, medical technology and devices, care services and health-related segments, including preventative care. Impilo is led by five partners with nearly 80 years of experience from investments in the Nordic region. Today the company has SEK 3 bn in commitments from Nordic and international investors.

    Read the whole news at Cision

See more news

Media

We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Go to Cision

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.